|Articles|October 4, 2019

Cerebrospinal Fluid Profiling of Host Responses May Be Key to Early AFM Diagnosis

In results presented at IDWeek2019, investigators demonstrated a distinct “signature” of AFM in blinded cerebrospinal fluid samples >80% of the time.

The etiology of acute flaccid myelitis (AFM) has proved difficult to pinpoint. Although previous studies have shown links to viral infections, such as enterovirus, West Nile, and Powassan, no study has yet established causality.

According to the US Centers for Disease Control and Prevention, there have been more than 585 cases of AFM in the United States since 2014, with patients reporting extreme weakness in 1 or more limbs, even partial paralyzation, usually within a month of a respiratory or gastrointestinal illness.

Investigators have particular trouble with the early detection of enterovirus (EV)-associated AFM because EVs are rarely isolated from cerebrospinal fluid. Also, diagnosis is dependent on clinical and radiological data that is largely subjective, with no specific biomarkers to date.

A research team with the University of California, San Francisco has discovered a novel approach to diagnosis of AFM, which relies on host transcriptional biomarkers from cerebrospinal fluid. In results presented at IDWeek 2019, investigators demonstrated a distinct “signature” of AFM in blinded samples >80% of the time. Benjamin J. Briggs, MD, PHD, clinical fellow, pediatrics, at University of California, San Francisco, and presenting author, discussed the results with Contagion® (see video).

Relying on existing and newly generated data from a clinical cerebrospinal fluid metagenomic assay for pathogen identification, investigators used that to interrogate the host response at the transcriptome level by RNA sequencing. Using the resulting data, the team created statistical classification models to discern viral infections associated with AFM, such as EV-D68, EV-A71, West Nile virus, and Powassan virus.

Approximately 50 cerebrospinal fluid samples were analyzed and split into independent training and test sets.

“We were able to demonstrate a distinct signature of AFM that was able to predict the virus associated with AFM in blinded test samples with >80% accuracy,” investigators reported. “The key transcriptional features that best discriminated EV-A71 from EV-D68-associated AFM involved protein targeting, viral transcription, viral gene expression, and translation initiation pathways.”

This novel approach to AFM detection may allow for earlier diagnosis, which would improve patient outcomes, the team concluded.

The study, Cerebrospinal fluid profiling of the human host response reveals species-specific enterovirus biosignatures in acute flaccid myelitis cases, was presented as a late breaking oral abstract on Friday, October 4, 2019, at IDWeek in Washington, DC.


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.